Heat Biologics Announces Proposed Public Offering of Common Stock
March 22 2017 - 4:04PM
Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the
development of immunotherapies designed to activate a patient’s
immune system against cancer, announced that it intends to offer
for sale shares of its common stock in an underwritten public
offering. The Company intends to use the net proceeds from
this offering to continue to fund its and its subsidiaries’
clinical and preclinical trials, for working capital and general
corporate purposes, as well as to acquire, license or invest in
complementary businesses, technologies, product candidates or other
intellectual property. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Aegis Capital Corp. is acting as the sole
book-running manager for the offering.
The shares described above are being offered by
Heat pursuant to a shelf registration statement (File No.
333-199274) that was previously filed with, and declared effective
by, the Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available on the
SEC's website located at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to this offering may be obtained, when available, from
Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019
or via telephone at 212-813-1010 or email:
prospectus@aegiscap.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an
immuno-oncology company developing novel therapies that are
designed to activate a patient’s immune system against cancer
utilizing an engineered form of gp96, a protein that activates the
immune system when cells die. Heat’s highly specific T
cell-stimulating therapeutic vaccine platform technologies, ImPACT
and ComPACT, in combination with other therapies, such as
checkpoint inhibitors, are designed to address three distinct but
synergistic mechanisms of action: robust activation of CD8+
“killer” T cells (one of the human immune system’s most potent
weapons against cancer); reversal of tumor-induced immune
suppression; and T cell co-stimulation to further enhance patients’
immune response. Currently, Heat is conducting a Phase 2
trial with HS-110 (viagenpumatucel-L) in combination with an
anti-PD-1 checkpoint inhibitor to treat patients with non-small
cell lung cancer (NSCLC) and a Phase 2 trial with HS-410
(vesigenurtacel-L) in patients with non-muscle invasive bladder
cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc.,
is developing therapeutic and preventative vaccines to treat
infectious diseases based on Heat’s gp96 vaccine technology, with a
current focus on the development of a Zika vaccine in conjunction
with the University of Miami.
For more information, please visit
www.heatbio.com.
Forward Looking Statements
This press release includes forward-looking
statements on our current expectations and projections about future
events, including statements regarding the proposed public
offering. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions. These
statements are based upon current beliefs, expectations and
assumptions and include statements regarding the proposed public
offering as well as Heat’s ongoing clinical programs and potential
licensing or acquisition of assets. These statements are
subject to a number of risks and uncertainties, many of which are
difficult to predict, including market conditions, the satisfaction
of customary closing conditions related to the proposed offering,
the success of Heat’s clinical programs, the ability to locate
suitable licensing and acquisition targets, and the other factors
described in Heat's filings with the SEC. The information in
this release is provided only as of the date of this release, and
we undertake no obligation to update any forward-looking statements
contained in this release based on new information, future events,
or otherwise, except as required by law.
CONTACT:
Heat Biologics, Inc.
Jennifer Almond
Investor and Media Relations
919-240-7133
investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Apr 2023 to Apr 2024